top of page
ADVISOR PHOTO 2024_JOHN NIELAND.jpg

John is a biotech and startup executive with 30 years of experience in the pharmaceuticals industry. He served as Director of Research at MediGene AG, before founding MetaIQ ApS to develop small-molecule compounds to treat neurological diseases. Currently, he is co-founder of the clinical-stage vaccine company 2A Pharma and CNS company 2N Pharma, and is supporting continued development of small molecule inhibitors to target cell metabolism. John is also Associate Professor and Head of the Molecular Pharmacology Department at Aalborg University, Denmark. 

 

John earned a Master in Biochemistry from the University of Amsterdam (1992) and a PhD in Immunology from Vrije Universiteit Amsterdam (1996). 

John Nieland, PhD 
Product Development
1.jpg

Numiera Therapeutics Inc

225 S Broadway 9533

Denver CO 80209-9998

©2024 Numiera Therapeutics

bottom of page